Merck & Co., Inc. (MRK) and CEPI team up to enhance Ebola vaccine accessibility in low- and middle-income countries by launching a $30 million program. The goal is to make the vaccine more affordable and easier to distribute, addressing cost and logistical challenges.

CEPI’s partnership with Merck will focus on improving the manufacturing process for Ervebo, Merck’s WHO-prequalified Ebola vaccine. Current production complexity makes the vaccine costly and challenging to produce at scale. Upgrades aim to increase yield, extend shelf life, and allow for standard refrigerator storage for several months.

MSD collaborates with Hilleman Laboratories to develop the updated vaccine, exploring options to supply public-sector buyers in low- and middle-income countries at a lower price. CEPI’s funding supports Hilleman’s clinical development work, aiming to enhance vaccine accessibility and affordability in underserved regions.

Merck raises revenue outlook, forecasting $70 billion from new growth drivers by the mid-2030s. Cardiometabolic and respiratory treatments expected to generate $20 billion in sales, while infectious disease drugs projected to contribute $15 billion. The company accelerates drug launches to combat competition to blockbuster therapy Keytruda.

Merck & Co., Inc. (MRK) is a global healthcare leader specializing in prescription medicines, vaccines, biologic therapies, and animal health products to enhance and save lives. The company focuses on innovation and development in the healthcare industry to address global health challenges and improve access to essential treatments.

Read more at Yahoo Finance: Merck & Co., Inc. (MRK) and CEPI Launch Effort to Make Ebola Vaccine Cheaper and Easier to Distribute